Looks like Novo is buying almost every diabetes treatment it can get hold of, their competitors have no choice but to follow suit if they want a piece of future diabetes treatment revenue. Novo could eventually purchase PMCB but so could Lilly, Merck, Sanofi, Gilead, Glaxo, Bristol-Myers Squibb, etc.